作者
David Mataix-Cols, Lorena Fernández De La Cruz, Benedetta Monzani, David Rosenfield, Erik Andersson, Ana Pérez-Vigil, Paolo Frumento, Rianne A De Kleine, JoAnn Difede, Boadie W Dunlop, Lara J Farrell, Daniel Geller, Maryrose Gerardi, Adam J Guastella, Stefan G Hofmann, Gert-Jan Hendriks, Matt G Kushner, Francis S Lee, Eric J Lenze, Cheri A Levinson, Harry McConnell, Michael W Otto, Jens Plag, Mark H Pollack, Kerry J Ressler, Thomas L Rodebaugh, Barbara O Rothbaum, Michael S Scheeringa, Anja Siewert-Siegmund, Jasper AJ Smits, Eric A Storch, Andreas Ströhle, Candyce D Tart, David F Tolin, Agnes Van Minnen, Allison M Waters, Carl F Weems, Sabine Wilhelm, Katarzyna Wyka, Michael Davis, Christian Rück, Margaret Altemus, Page Anderson, Judith Cukor, Claudia Finck, Gary R Geffken, Fabian Golfels, Wayne K Goodman, Cassidy Gutner, Isobel Heyman, Tanja Jovanovic, Adam B Lewin, Joseph P McNamara, Tanya K Murphy, Seth Norrholm, Paul Thuras, DCS Anxiety Consortium
发表日期
2017/5/1
来源
JAMA psychiatry
卷号
74
期号
5
页码范围
501-510
出版商
American Medical Association
简介
Importance
Whether and under which conditions D-cycloserine (DCS) augments the effects of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders is unclear.
Objective
To clarify whether DCS is superior to placebo in augmenting the effects of cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders and to evaluate whether antidepressants interact with DCS and the effect of potential moderating variables.
Data Sources
PubMed, EMBASE, and PsycINFO were searched from inception to February 10, 2016. Reference lists of previous reviews and meta-analyses and reports of randomized clinical trials were also checked.
Study Selection
Studies were eligible for inclusion if they were (1) double-blind randomized clinical trials of DCS as an augmentation strategy for exposure-based cognitive behavior therapy and (2 …
学术搜索中的文章
D Mataix-Cols, LF De La Cruz, B Monzani… - JAMA psychiatry, 2017